PE20090168A1 - Composiciones farmaceuticas de buprenorfina y naloxona - Google Patents

Composiciones farmaceuticas de buprenorfina y naloxona

Info

Publication number
PE20090168A1
PE20090168A1 PE2008000413A PE2008000413A PE20090168A1 PE 20090168 A1 PE20090168 A1 PE 20090168A1 PE 2008000413 A PE2008000413 A PE 2008000413A PE 2008000413 A PE2008000413 A PE 2008000413A PE 20090168 A1 PE20090168 A1 PE 20090168A1
Authority
PE
Peru
Prior art keywords
buprenorphine
naloxone
pharmaceutical compositions
unit dosage
tetrahidronororipavine
Prior art date
Application number
PE2008000413A
Other languages
English (en)
Inventor
Christopher Bourne Chapleo
Neil Hyde
Original Assignee
Reckitt Benckiser Healthcare
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reckitt Benckiser Healthcare filed Critical Reckitt Benckiser Healthcare
Publication of PE20090168A1 publication Critical patent/PE20090168A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physiology (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

REFERIDA A UNA COMPOSICION FARMACEUTICA ANALGESICA, EN FORMA DE DOSIFICACION PARENTERAL UNITARIA O EN FORMA DE DOSIFICACION UNITARIA PARA LA MUCOSA O DERMIS, QUE COMPRENDE BUPRENORFINA (N-CICLOPROPILMETIL-7[ALFA]-[1-(S)-HIDROXI-1,2,2-TRIMETIL-PROPIL]6,14-ENDOETAN-6,7,8,14-TETRAHIDRONORORIPAVINA) Y NALOXONA (1-N-ALIL-14-HIDROXINORHIDRO-MORFINONA), DONDE LA BUPRENORFINA SE ENCUENTRA EN UNA CANTIDAD DE ENTRE 10 uG Y 8 MG
PE2008000413A 2007-03-01 2008-02-29 Composiciones farmaceuticas de buprenorfina y naloxona PE20090168A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0703968A GB2447016A (en) 2007-03-01 2007-03-01 Buprenorphine/naloxone compositions

Publications (1)

Publication Number Publication Date
PE20090168A1 true PE20090168A1 (es) 2009-03-19

Family

ID=37965735

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000413A PE20090168A1 (es) 2007-03-01 2008-02-29 Composiciones farmaceuticas de buprenorfina y naloxona

Country Status (17)

Country Link
US (1) US20110046172A1 (es)
EP (1) EP2129380A1 (es)
JP (2) JP2010520186A (es)
KR (1) KR20090117891A (es)
CN (1) CN101626766B (es)
AR (1) AR065579A1 (es)
AU (1) AU2008220574A1 (es)
BR (1) BRPI0807908A2 (es)
CA (1) CA2678582A1 (es)
CL (1) CL2008000606A1 (es)
GB (1) GB2447016A (es)
HK (1) HK1139871A1 (es)
MX (1) MX2009009131A (es)
PE (1) PE20090168A1 (es)
TW (1) TWI451868B (es)
WO (1) WO2008104738A1 (es)
ZA (1) ZA200905664B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
US8663687B2 (en) 2001-10-12 2014-03-04 Monosol Rx, Llc Film compositions for delivery of actives
US11207805B2 (en) 2001-10-12 2021-12-28 Aquestive Therapeutics, Inc. Process for manufacturing a resulting pharmaceutical film
US20110033542A1 (en) 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
US7357891B2 (en) 2001-10-12 2008-04-15 Monosol Rx, Llc Process for making an ingestible film
US20070281003A1 (en) 2001-10-12 2007-12-06 Fuisz Richard C Polymer-Based Films and Drug Delivery Systems Made Therefrom
US8603514B2 (en) 2002-04-11 2013-12-10 Monosol Rx, Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US10285910B2 (en) 2001-10-12 2019-05-14 Aquestive Therapeutics, Inc. Sublingual and buccal film compositions
US20190328679A1 (en) 2001-10-12 2019-10-31 Aquestive Therapeutics, Inc. Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US8900498B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for manufacturing a resulting multi-layer pharmaceutical film
US8900497B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for making a film having a substantially uniform distribution of components
US8765167B2 (en) 2001-10-12 2014-07-01 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
UA102128C2 (en) * 2008-12-05 2013-06-10 Х. Луннбек А/С Nalmefene hydrochloride dihydrate
US8475832B2 (en) 2009-08-07 2013-07-02 Rb Pharmaceuticals Limited Sublingual and buccal film compositions
CA2792878C (en) * 2010-03-12 2019-10-22 Government Of The Usa, As Represented By The Sec., Dept. Of Health And Human Services Agonist/antagonist compositions and methods of use
US8529914B2 (en) * 2010-06-28 2013-09-10 Richard C. Fuisz Bioactive dose having containing a material for modulating pH of a bodily fluid to help or hinder absorption of a bioactive
US9149959B2 (en) 2010-10-22 2015-10-06 Monosol Rx, Llc Manufacturing of small film strips
SG10201610097WA (en) * 2011-08-18 2017-01-27 Biodelivery Sciences Int Inc Abuse-resistant mucoadhesive devices for delivery of buprenorphine
HRP20211539T1 (hr) 2011-09-19 2021-12-24 Orexo Ab Sublingvalne tablete otporne na zloupotrebu koje sadrže buprenorfin i nalokson
SG10202012743WA (en) * 2011-12-21 2021-01-28 Biodelivery Sciences Int Inc Transmucosal drug delivery devices for use in chronic pain relief
CN103690495B (zh) * 2013-12-19 2015-04-08 贵州景峰注射剂有限公司 注射用盐酸纳洛酮的冷冻干燥方法
JP2017508800A (ja) 2014-03-14 2017-03-30 オーピアント ファーマシューティカルズ， インコーポレイテッド 経鼻薬物製品およびその使用方法
US9480644B2 (en) 2014-03-14 2016-11-01 Opiant Pharmaceuticals, Inc. Nasal drug products and methods of their use
US9561177B2 (en) 2014-03-14 2017-02-07 Adapt Pharma Limited Nasal drug products and methods of their use
US10085937B2 (en) 2014-03-14 2018-10-02 Adapt Pharma Limited Nasal drug products and methods of their use
CA3022840A1 (en) 2016-05-05 2017-11-09 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine compositions
US11273131B2 (en) 2016-05-05 2022-03-15 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8332556D0 (en) * 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
JPH1036265A (ja) * 1996-07-19 1998-02-10 Nitto Denko Corp ブプレノルフィン経皮吸収製剤
AR031682A1 (es) * 1999-11-19 2003-10-01 Reckitt Benckiser Helthcare Uk Composiciones farmaceuticas
US20050191340A1 (en) * 2002-08-09 2005-09-01 Gruenenthal Gmbh Opioid-receptor antagonists in transdermal systems having buprenorphine
AU2003283055A1 (en) * 2002-08-09 2004-02-25 Grunenthal Gmbh Opioid-receptor antagonists in transdermal systems having buprenorphine

Also Published As

Publication number Publication date
TWI451868B (zh) 2014-09-11
US20110046172A1 (en) 2011-02-24
BRPI0807908A2 (pt) 2014-06-17
CN101626766B (zh) 2013-07-10
KR20090117891A (ko) 2009-11-13
AU2008220574A1 (en) 2008-09-04
HK1139871A1 (en) 2010-09-30
CL2008000606A1 (es) 2008-10-03
MX2009009131A (es) 2009-09-03
GB0703968D0 (en) 2007-04-11
CA2678582A1 (en) 2008-09-04
JP2010520186A (ja) 2010-06-10
ZA200905664B (en) 2010-10-27
EP2129380A1 (en) 2009-12-09
TW200843773A (en) 2008-11-16
CN101626766A (zh) 2010-01-13
AR065579A1 (es) 2009-06-17
WO2008104738A1 (en) 2008-09-04
GB2447016A (en) 2008-09-03
JP2014196325A (ja) 2014-10-16

Similar Documents

Publication Publication Date Title
PE20090168A1 (es) Composiciones farmaceuticas de buprenorfina y naloxona
CL2011002248A1 (es) Composicion farmaceutica oral de liberacion inmediata que comprende oxicodona y naloxona en una proporcion 2:1 en peso; uso de la composicion farmaceutica para tratar dolor intercurrente en paciente que sufren de dolor.
CL2012000313A1 (es) Composición de dosificación de película que comprende una matriz portadora, entre 2-16 mg de buprenorfina, entre 0,5-5 mg de naloxona y un tampón que proporciona un ph local entre 2-4; procedimiento de preparación; uso en el tratamiento de la dependencia de narcóticos en un usuario.
TW200621317A (en) Pharmaceutical composition
AR065581A1 (es) Mejoras en composiciones medicinales o relativas a las mismas
CR20140340A (es) Formas farmacéuticas de dosificación oral resistente a interferencias que comprenden un analgésico opioide
CL2007003609A1 (es) Compuestos derivados de dihidropiridinas sustituidas; proceso de preparacion; compuestos intermediarios; composicion farmaceutica; proceso para producir la composicion farmaceutica; y uso en el tratamiento de una enfermedad mejorada con la inhibicion
BR122017015098B8 (pt) formulações farmacêuticas de liberação imediata que contêm hidrato de propileno glicol de dapagliflozina
UY30440A1 (es) Nuevos compuestos
ECSP088974A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
CL2011002858A1 (es) Uso de una composicion farmaceutica transmucosa oral que comprende dexmedetomidina y una sal farmaceuticamente aceptable y un excipiente farmaceuticamente aceptable para preparar un medicamento util para tratar o prevenir el dolor.
TW200800987A (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
DE602005004312D1 (de) Analgistische Darreichungsform, die nicht parenteral oder inhalation dosiert werden können
CL2013001136A1 (es) Un agente inhibitorio de la fosfodiesterasa 7 (pde7) para ser usado en el tratamiento o la reduccion de la posibilidad de una adiccion; y composicion farmaceutica, forma de dosificacion unitaria y kit farmaceutico que incluyen al inhibidor de fosfodiesterasa 7 (pde7) y un agente terapeutico adicional.
EA201070237A1 (ru) Четвертичные опиоидные карбоксамиды
MY156913A (en) Oral administration of peripherally-acting opioid antagonists
PE20081799A1 (es) Mejoras en composiciones medicinales o relativas a las mismas
MX2009004017A (es) Usos de los compuestos carboxi-amido triazol y sus sales.
BR112013016862A2 (pt) combinação de um agonista de opioide e um antagonista de opioide no tratamento de doença de parkinson
UA93709C2 (ru) 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций
ECSP088889A (es) Forma nueva de administración de racecadotril
WO2007112272A3 (en) Formulations of low dose diclofenac and beta-cyclodextrin
TW200738269A (en) Oral delivery of therapeutic agents using tight junction agonists
BRPI0816798A2 (pt) composto, composição farmacêutica, métodos para inibir a ação do glicogênio sintase cinase-3, e para tratar, prevenir ou melhorar uma doença, uso de um composto, e, artigo de fabricação
PE20090625A1 (es) Composicion farmaceutica que contiene buprenorfina y nalmefeno

Legal Events

Date Code Title Description
FC Refusal